Myeloma Overexpressed (MYEOV) is closely related to cell growth and differentiation in many cancer types. However, the role of this protein-coding gene in pancreatic ductal adenocarcinoma (PDAC) has rarely been investigated. In this study, we demonstrated that MYEOV was higher expressed in tumor tissues compared with adjacent normal pancreas tissues (ANPTs) both in mRNA and protein levels. We also performed bioinformatic analysis and found high MYEOV expression was positively correlated with tumor differentiation (P = 0.004), lymph node metastasis (P = 0.016) and TNM stage (P = 0.001). Moreover, Kaplan–Meier and Cox proportional-hazards analyses indicated that high MYEOV expression was significantly associated with poor survival in patients with PDAC and that MYEOV was an independent prognostic factor for overall survival in patients with PDAC. Geneset Enrichment Analysis (GSEA) result showed that high expression of MYEOV facilitates glycolysis of tumor cells in PDAC and validated in cellular assays. In conclusion, our results suggest that MYEOV acts as an oncogene in PDAC and can therefore serve as a biomarker for the prognosis of patients with PDAC.

骨髓瘤过度表达 (MYEOV) 与许多癌症类型的细胞生长和分化密切相关。然而，这种蛋白质编码基因在胰腺导管腺癌（PDAC）中的作用却很少被研究。在这项研究中，我们证明，与邻近的正常胰腺组织（ANPT）相比，MYEOV 在肿瘤组织中的 mRNA 和蛋白质水平表达更高。我们还进行了生物信息学分析，发现MYEOV高表达与肿瘤分化程度（P = 0.004）、淋巴结转移（P = 0.016）和TNM分期（P = 0.001）呈正相关。此外，Kaplan-Meier 和 Cox 比例风险分析表明，高 MYEOV 表达与 PDAC 患者的不良生存率显着相关，并且 MYEOV 是 PDAC 患者总生存率的独立预后因素。基因组富集分析 (GSEA) 结果表明，MYEOV 的高表达促进 PDAC 中肿瘤细胞的糖酵解，并在细胞测定中得到验证。总之，我们的结果表明，MYEOV 作为 PDAC 的癌基因，因此可以作为 PDAC 患者预后的生物标志物。